The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.
The patent, entitled “Methods and Compositions for Treating Cancer,” covers a nucleic acid that encodes a chimeric protein whose domains can be used to treat certain types of cancer by binding to specific hormone receptors and activating T-cells.
The patent was invented by Drs. Jose Conejo-Garcia and Alfredo Perales-Puchalt, both formerly of The Wistar Institute, to which the patent is assigned, along with Anixa’s majority-owned subsidiary, Certainty Therapeutics, which is the exclusive, world-wide licensee.
“Our novel CAR-T technology takes advantage of specific hormone-to-hormone receptor biology to address malignancies and has the potential to be the first successful CAR-T therapy against solid tumors,” Dr. Amit Kumar, chairman and CEO of Anixa, said in a statement.
“While our initial focus is on the treatment of ovarian cancer — with a Phase 1 clinical trial currently ongoing — the technology covered by the patent has broad application and could potentially also be used to treat other solid tumors by exploiting an anti-angiogenesis mechanism of action,” he added.
